CLDN18 and gastroesophageal junction adenocarcinoma: The clinical benefits of the mouse/human chimeric anti-CLDN18.2 mAb zolbetuximab (IMAB362) were demonstrated in the randomized phase III clinical trials GLOW (NCT03653507) and SPOTLIGHT (NCT03504397) (Shah et al., 2023; Shitara et al., 2023), and the FDA approved zolbetuximab plus chemotherapy for the treatment of gastric or gastroesophageal junction adenocarcinoma (G/GEJAC).